Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Contributed by: Business Wire

Logo

Tags

Research

Technology

Clinical Trials

Biotechnology

Pharmaceutical

Health

Science

Oncology

Artificial Intelligence

Other Science

CDK7

More Like This

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

GlobeNewswire associated0

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

GlobeNewswire associated0

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery